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A B S T R A C T
Objectives: To assess the risk of nosocomial transmission by conﬁrmed pulmonary tuberculosis (PTB)
patients in a high TB/HIV incidence environment.
Methods: Between November 2006 and April 2007, we carried out a cross-sectional survey of PTB
patients with positive smears or cultures at an academic tertiary hospital in the Western Cape, South
Africa.
Results: Of 394 conﬁrmed PTB patients, only 199 (50.5%) had a known HIV status, of whom 107 (53.8%)
were HIV-co-infected. Sensitivity testing for Mycobacterium tuberculosis (TB) was done in 49.3% of
patients with available cultures (140/284). Of these patients, 9.3% (13/140) had multidrug-resistant
(MDR) TB strains. The turnaround times (TAT) for culture and susceptibility testing were delayed: mean
TAT for cultures was 27 days (range 63 days) and for susceptibility testing was 42 days (range 63 days).
One ﬁfth of PTB patients (82/394) were diagnosed from wards that do not deal with TB on a daily basis.
PTB inpatients were hospitalized for an average of 13 days and were on average transferred twice. Only
14.2% of all PTB patients were notiﬁed to the South Africa Provincial Department of Health. Throughout
their hospitalization, PTB patients were potentially infectious.
Conclusions: The potential for nosocomial TB transmission in a setting of high TB and HIV co-infection
with a high MDR prevalence, inconsistent infection prevention and control measures, and delayed
diagnosis cannot be ignored. Barriers to TB infection control must urgently be addressed.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The tuberculosis (TB) epidemic is historically anchored in South
Africa’s Western Cape province, and long precedes the HIV
epidemic. This is despite the generally better socio-economic
status of the population and greater overall healthcare expenditure
in this region than in other provinces. Contributing factors include
overcrowding, alcohol abuse, poverty, and administrative neglect
of the National TB Programme (NTP).1 This traditional ‘Cape’
epidemic is now being signiﬁcantly augmented by an HIV-
associated TB epidemic.
Multidrug-resistant TB (MDR-TB), deﬁned as disease caused by
strains with resistance to at least isoniazid and rifampin,2 was ﬁrst
identiﬁed in theWestern Cape in 1985; within nine years, MDR-TB
accounted for 2% of TB isolates in this region.3 There is growing
evidence that institutional transmission is a critical factor in
epidemic HIV-associated TB and MDR-TB.4 Infection prevention* Corresponding author. Tel.: +27 021 938 5059; fax: +27 021 938 5065.
E-mail address: dsissolak@sun.ac.za (D. Sissolak).
1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.06.030and control (IPC) is only now becoming a feature of the global
strategy to control TB.5 In South Africa, IPC remains the
responsibility of individual healthcare facilities.6 There is an
urgent need to obtain data on nosocomial transmission and to
acknowledge the importance of IPC in protecting healthcare
workers (HCWs), other patients, and visitors at the hospital level.
The study setting was a 1291-bed academic tertiary teaching
hospital in Cape Town, South Africa, which received approximately
30–50% of provincial tertiary referrals, with a catchment popula-
tion of about two million people, mostly living in poor socio-
economic conditions. A primary healthcare clinic (PHCC) with
inpatient wards, speciﬁcally serving a deprived suburb with an
almost exclusively black African population, was temporarily
located within the hospital.
2. Methods
2.1. The setting
Smear microscopy forms the basis of the NTP in South Africa,7
although culture and susceptibility testing are available at theses. Published by Elsevier Ltd. All rights reserved.
Figure 1. Turnaround time (TAT) and the components that deﬁne the individual pulmonary TB inpatient’s ‘potential time of transmission’.
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carried out in the on-site laboratory of the National Health
Laboratory Service (NHLS), although at the time of this study,
identiﬁcation and susceptibility testingwere performed at another
local NHLS laboratory. All laboratory results are available
immediately to clinicians in the wards via a computer-based
laboratory information system. Individual clinicians remain
responsible for all decisions regarding treatment of their patients.
Clinicians are also responsible for notiﬁcation of all patients to the
TB control program.
2.2. Study population
All pulmonary TB (PTB) patients presenting to our hospital
between November 2006 and April 2007 were included in the
study. Patients were identiﬁed by their ﬁrst positive microbiolo-
gical specimen, either smear or a culture result, being reported by
the NHLS. If only smear-positive patients had been selected, the
study would not have taken into account the HIV-positive, who are
usually smear-negative but still infectious.8 Duplicate results from
the same patient were excluded from the database. Each patient
was also registered as either an outpatient or an inpatient,
dependant on which ward or outpatient clinic requested the ﬁrst
specimen within the study period.
2.3. Data collection and deﬁnitions
The laboratory information system for microbiology and
virology, as well as the hospital’s clinical software package, was
used for data collection and analysis. Patient variables included
date of specimen, ward or outpatient clinic from which micro-
biology was requested, patient age, sex, ethnic origin, HIV status
and/or viral load, date of starting anti-TB treatment, notiﬁcation,
and outcome (discharge, transferred, or death). TB notiﬁcation
forms were submitted by clinical staff from the wards and
outpatient clinics to the hospital administration. The date of
notiﬁcation was retrieved through the hospital administration
notiﬁcation register. The cut-off date for collecting data from the
notiﬁcation book was June 1, 2007, allowing two months for
laboratory results to be returned and notiﬁcation to be made. For
inpatients, the dates of admission and discharge and the number of
transfers within the hospital during this admission period were
noted.
Microbiological variables included the date of receipt of the
sample, the date of reporting to the ward/clinic, as well as the
results of smear, culture, and drug susceptibility testing, if
available. In accordance with the national TB control policy, TB
is chieﬂy diagnosed on smear microscopy, and culture and drugsusceptibility testing are done only at the request of the clinician.
The dates of receipt of the sample and of report frommicrobiology
served for the calculation of the turnaround time (TAT) (Fig. 1).
2.4. The potential to transmit
Transmissibility continues for at least one week after the start
of TB treatment, and this period may be even longer for those with
extensive disease or MDR-TB.9 We deﬁned the ‘potential time of
transmission’ of TB within the hospital as the infectious time span
of PTB inpatients from date of admission to seven days after
starting anti-TB therapy (Fig. 1). As the time of treatment start was
not electronically registered at our hospital, we assumed that the
date of commencement of treatment corresponded with the date
that the ﬁrst microbiological report became available on the
hospital computer system. In those PTB patients who had had a
positive specimen seven days or more prior to their registered
admission, the potential to transmit was coded as zero, as we
assumed these patients had started treatment and were no longer
infectious. Only patients aged14 years contribute signiﬁcantly to
TB transmission, therefore we excluded those <14 years from this
calculation.10
2.5. Statistical analysis
SPSS 13.0 (SPSS Inc., Chicago, IL, USA)was used for the statistical
analysis. One-way analysis of variance (one-way ANOVA)was used
for testing the equality of three means at one time, and logistic
regression analysis for assessing effects of potential risk factors, the
results being given as odds ratios (OR) with associated 95%
conﬁdence intervals (CI) and p-values. A p-value  0.05 was
considered signiﬁcant.
2.6. Ethics
The data were collected in strict accordance with Good Clinical
Practice.11 The study was approved by the Committee for Human
Research, StellenboschUniversity, Cape Town, South Africa. Ethical
Principles for Medical Research Involving Human Subjects12 apply
to all research. Informed consent was not required since it was a
cross-sectional survey and data were extracted conﬁdentially and
anonymously.
3. Results
During the 6-month study period, 394 patients with micro-
biologically conﬁrmed PTB presented as either outpatients (n = 68;
17.3%) or inpatients (n = 326; 82.7%). There were 193 (49.0%)
Figure 2. Histogram of sex and age (4-year intervals) of 394 patients diagnosed with pulmonary TB at a tertiary teaching hospital, Western Cape, South Africa, November 1,
2006–April 30, 2007.
Figure 3. Histogram of HIV status and age (4-year intervals) at a tertiary teaching hospital, Western Cape, South Africa, November 1, 2006–April 30, 2007.
D. Sissolak et al. / International Journal of Infectious Diseases 14 (2010) e423–e428 e425female and 201 (51.0%) male PTB patients, with a mean age of 32.5
years (median 31, mode 1, range 80, SD 18.43 years); 118 (29.9%)
were children aged <14 years. Fig. 2 illustrates the relationship
between sex and age in the cohort. More children and young adults
were females, whilemales dominated in the later age groups. In terms
of ethnicity, 180 (45.7%) patients were of African origin, 199 (50.5%)
colored, 11 (2.8%) white, and four (1.0%) were Asian.
Information on HIV status was available for 199/394 (50.5%)
patients, of whom 107 (53.8%) were HIV-positive and 92 (46.2%)
HIV-negative. A histogram of HIV status and age (Fig. 3) shows thatTable 1
Contingency table for HIV co-infection in 199 HIV-tested patients diagnosed with PTB
Variable Subgroup Total n Known HIV status
Age (years) 17–32 177 107
0–16 and 33+ 217 92
Sex Female 193 103
Male 201 96
Ethnic origin African 180 99
Colored 199 95
PTB, pulmonary tuberculosis; OR, odds ratio; CI, conﬁdence interval.young adults, especially those between 21 and 28 years of age, are
more likely to be HIV-positive (Fig. 3). Applying logistic regression
for independent effects on HIV co-infection revealed that African
ethnic origin (OR 3.61, 95% CI 2.01–6.47, p = 0.00001), female sex
(OR 2.39, 95% CI 1.36–4.21, p = 0.00243), and age 17–32 years (OR
2.37, 95% CI 1.34–4.18, p = 0.00275) were signiﬁcantly and
independently correlated with a positive HIV status (Table 1).
Of 394 patients with pulmonary TB, microscopy alone was
requested in 110 and culture was requested in 284. Eighty-ﬁve of
284 patients with positive cultures were smear-positive, giving anat Tygerberg Hospital over the period November 1, 2006–April 30, 2007
HIV status OR 95% CI p-Value
Positive Negative
68 (63.6%) 39 (36.4%) 2.37 1.34–4.18 0.00275
39 (42.4%) 53 (57.6%)
66 (64.1%) 37 (35.9%) 2.39 1.36–4.21 0.00243
41 (42.7%) 55 (57.3%)
69 (69.7%) 30 (30.3%) 3.61 2.01–6.47 0.00001
37 (38.9%) 58 (61.1%)
Table 2
Turnaround times of smears, cultures, and sensitivity testing in 394 patients with conﬁrmed PTB over a 6-month period (November 1, 2006–April 30, 2007)
Turnaround time Total n Missinga Mean SD Min Max Range % available within CDC standards
Smears (h) 86 24 9 8 1 26 25 91.9
Cultures (days) 273 33 27 10 10 73 63 33.3
Sensitivity testing (days) 89 51 42 13 19 82 63 22.5
PTB, pulmonary tuberculosis; SD, standard deviation; CDC, Centers for Disease Control and Prevention.
a No dates of report from Microbiology available.
Table 3
Wards from which specimens from PTB patients were requested between November 1, 2006 and April 30, 2007; PTB patients with known HIV status according to ward
Wards/OPC from which specimens were requested PTB patients, n (%) HIV status, n (%) Total
Positive Negative
PHCC clinic (temporarily included on hospital premises) 48 (12.2%) 12 (75%) 4 (25%) 16
Wards/OPC without TB routine (surgery, neurosurgery, obstetrics, orthopedics, surgical ICU) 82 (20.8%) 18 (52.9%) 16 (47.1%) 34
Wards/OPC with TB routine (internal medicine, pediatrics, internal medicine ICU) 264 (67.0%) 77 (51.7%) 72 (48.3%) 149
Total n 394 107 92 199
PTB, pulmonary tuberculosis; OPC, outpatient clinic; PHCC, primary health care clinic; ICU, intensive care unit.
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testing was performed in 140 of the 284 patients with culture
results (49.3%). Sensitive strains were reported in 111/140 (79.3%).
There were three (2.1%) strains resistant to rifampin alone, 13
(9.3%) resistant only to isoniazid, and 13 (9.3%) resistant to both
rifampin and isoniazid (MDR strains). Six of the MDR strains were
also resistant to ethambutol.
There was no signiﬁcant association between MDR status and
age (OR 1.07, 95% CI 0.31–3.69, p = 0.91104), sex (OR 2.15, 95% CI
0.64–7.16, p = 0.20776), ethnic origin (OR 1.02, 95% CI 0.32–3.22,
p = 0.96889), or HIV status (OR 2.8, 95% CI 0.54–14.82, p = 0.21103)
in this cohort.
The mean TAT for smear microscopy from receipt in the
laboratory was 9 h (n = 86; SD 8, range 25 h), and 79/86 (91.9%)
smear resultswere availablewithin 24 h (Table 2). TB cultures took an
average of 27 days (n = 273; SD 10, range 63 days), while 91/273
(33.3%) were available within 21 days (Table 2). Susceptibility test
results were reported in an average of 42 days (n = 89; SD 13, range
63 days), with 20/89 (22.5%) results available within 30 days
(Table 2). However, it should be noted that at times, susceptibility
testing was only requested by clinicians after receipt of culture
results, and therefore these ﬁgures may not be an accurate
representation of laboratory activity.
The majority of specimens, 264/394 (67.0%), were requested
from wards with TB routine, while 82/394 (20.8%) originated fromTable 4
Frequency of inpatient days, number of ward transfers, and potential time of transmissio
30, 2007
Variable Mean Median
Number of inpatient days 13.4 10
Number of ward transfers 2 2
Potential time of transmission (days) 22 23
PTB, pulmonary tuberculosis; SD, standard deviation. Four patients without date of rep
Table 5
Inferential analysis of patients with conﬁrmed PTB between November 1, 2006 and Apr
were provided by the Information Management Unit
Numerator Denominator
1 n patients with PTB Total n of patients
2 n inpatients with PTB Total n of inpatients
5 n deaths in inpatients with PTB Total n of PTB inpatients
3 n deaths inpatients Total n of inpatients
6 n notiﬁed PTB patients Total n of PTB patients
PTB, pulmonary tuberculosis.wards not dealing with TB on a daily basis (Table 3). The HIV status
of PTB patients did not differ signiﬁcantly between departments:
51.7% (77/149) PTB patients on wards with TB routine were HIV-
positive, compared to 52.9% (18/34) PTB patients onwardswithout
(Table 3). PTB patients from the PHCC had a much higher
proportion of HIV infection: 12/16 (75%) (Table 3), which, due
to the much smaller number of patients, was not statistically
evaluated.
PTB inpatients with MDR-TB had a longer average length of
hospital stay of 36 days (n = 9, 95% CI 25.3–46.3) compared to those
without MDR-TB, who stayed an average of 17 days (n = 107, 95%
CI 13.9–20.1), as calculated with one-way ANOVA. Among those in
whom sensitivity testing was not requested, the average length of
stay was 12 days (n = 209, 95% CI 10.3–14.6).
There were 276 inpatients aged 14 years who had the
potential to transmit TB within the given time period (Table 4).
They spent an average of 13.4 days in hospital (SD 14, range 144
days) and were transferred twice (SD1, range 7) within the hospital
to various wards and units. Their average ‘potential time of
transmission’ was 22 days (SD 17, range 97 days) (Table 4).
During the 6-month period, the prevalence was 510/100 000
population (394/77 229) for both PTB inpatients and outpatients,
and for inpatients only was 1300/100 000 population (326/25 059)
(Table 5), the denominators of patient statistics excluding
duplicates. The mortality rate associated with PTB was 9.4% (37/n based on 276 inpatients with infectious PTB between November 1, 2006 and April
SD Min. Max. Range
14 1 145 144
1 1 8 7
17 0 97 97
ort from Microbiology.
il 30, 2007; the basic statistics of absolute patient numbers (without duplications)
Proportion Rate
(394/77229) Prevalence among all patients: 510/100000
(326/25059) Prevalence among inpatients: 1300/100000
(37/326) Crude death rate of PTB inpatients: 11.3%.
(1055/25059) Crude death rate of inpatients: 4.2%
(56/394) Notiﬁcation rate: 14.2%
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the hospital in the given time period (Table 5). Of 394 PTB patients,
56 (14.2%) were notiﬁed by the time the study follow-up was
completed (Table 5).
4. Discussion
The results reﬂect the high burden of PTB both in the Western
Cape and in sub-districts around the hospital.13,14 The percentage
of pediatric TB cases was high at 29.9% (n = 118), considering that
children under 15 years usually contribute about 15% of the total
case load of TB in low income countries.15 However, children are
more difﬁcult to diagnose in primary healthcare settings andmight
therefore be over-represented in this study.
The MDR-TB prevalence rate of culture-tested PTB patients
found in our survey, 9.3% (13/140), is much higher than that
reported in various surveys conducted in theWestern Cape. Schaaf
et al. reported a prevalence of 5.7% in a review of culture-conﬁrmed
childhood TB in the Western Province between 2003 and 2005,16
and recently reported a prevalence of 5.4% at Tygerberg Children’s
Hospital.17 The National survey of 2007 demonstrated an overall
MDR-TB prevalence of 2.9%.14 Since drug sensitivity testing was
not done routinely for all patients at our hospital, the high MDR
ratemay reﬂect selection bias. No comment can bemade about the
prevalence of extensively drug resistant TB (XDR), deﬁned as TB
that is resistant to isoniazid, rifampin, quinolones, and at least one
of three injectable second-line drugs,18 since routine testing of
second-line drugs was not implemented at the time of our study.
The high TB/HIV co-infection rate in theWestern Cape19–22 was
conﬁrmed by this survey, however, more than half of the patients
presenting with PTB had an unknown HIV status (195/394). Since
this study was based on a review of laboratory data and not on a
review of individual patient notes, some of the patients with
known HIV status determined in the community might have been
missed. However, similar low levels of HIV testing have been
documented previously: only 22% of patients with TB underwent
HIV testing in South Africa in 2005, despite a national policy of
providing counseling and testing for all patients with TB.23 HIV
testing among patients with TB is one of the most essential
components of TB/HIV integration andmay serve as a critical entry
point into HIV treatment and care in settings with both
conditions.24 Our ﬁndings reﬂect the lack of local strong TB/HIV
collaborative activities and indicate an urgent need for integration
of the responses of HIV and TB programs in a high incidence
setting.
The major burden of TB–HIV co-infection was found in young
adults, in the African ethnic group and in females, in agreement
with the ﬁndings of Lawn et al.22 HIV-uninfected individuals with
TB are more infectious,25 therefore the male and colored ethnic
patient group of our cohort that were signiﬁcantly associated with
a lower HIV-positive status, may represent a key source of TB
transmission in the hospital and should particularly be targeted.
The TATs recommended by the Centers for Disease Control and
Prevention (CDC) for TB microscopy, culture, and susceptibility
testing are 24 h, 21 days, and 30 days, respectively.26 European
guidelines specify that 90% of respiratory specimens should meet
these criteria.27 In addition, European guidelines recommend rapid
determination of rifampin resistance within 1–2 working days. In
this study, 91.9% of microscopy results were available within 24 h,
but only 33.3% of cultures and 22.5% of susceptibility tests met the
TAT guidelines. Delays in laboratory diagnosis constitute a barrier
to the early initiation of treatment and prolong the duration of
transmissibility.
Over the 6-month period, 276 PTB inpatients aged 14 years
had an average ‘potential time of transmission’ in our hospital of 22
days. Since their average hospitalization period was 13 days, theirtotal length of hospital stay can be considered potentially
infectious.
The authors are aware of several limitations associated with
this calculation. The exact date of the start of TB treatment was not
available, thus the calculation does not take into account the
possibility of either pre-treatment or empiric treatment, which
would reduce the time of transmission, or clinician delay in
responding to laboratory results, which would prolong it. Also, the
‘potential time of transmission’ can be assumed to bemuch greater
for MDR-TB and/or HIV-infected PTB patients, in whom the
diagnosis of TB and the institution of effective treatment is more
likely to be delayed, and whose response to treatment is
slower.24,28 In addition, this survey did not identify patients
whowere hospitalizedmore than once in the study period.We can
only extrapolate the period of infectiousness.
Another indicator of nosocomial transmission is the occupa-
tional risk of acquiring TB disease. During our study period, 16
HCWs were ofﬁcially reported to have been infected with TB. It is
thought that under-reporting by the HCWs to Occupational Health
may occur due to a fear of stigma. In addition, HCWs in the setting
of a generalized HIV epidemic are more likely to be HIV-infected
themselves,29 and if infected, they are more likely to develop TB.30
Given the high potential for transmission of TB in this setting,
infection control precautions are crucial for reducing the risk of
nosocomial transmission. On top of sheer numbers of infectious
PTB patients, TB exposure can be high owing to inadequate
isolation facilities, inconsistent use of protective gear, staff
shortages, a heavy workload for nurses, lack of essential resources,
and ineffective organization of services.4,31
Similar to most state health facilities in South Africa, ﬁnances
were restricted at our hospital, impeding implementation of even
low-cost TB-IPC measures. Recent routine IPC audits at different
departments of our hospital showed inconsistently applied
transmission-based precautions, even where known TB cases
were admitted on a routine basis. There seemed to be a lack of
knowledge on the appropriate use of surgical masks and N95-
respirators, including their previous ﬁt test. There was a partially
functioning mechanical ventilation system, with only a limited
number of rooms having access to natural ventilation. The
hospital’s infectious diseases outpatient clinic was not dedicated
to TB management alone. TB patients were admitted throughout
the hospital, some of them only diagnosed later during their stay.
Therewas no segregation of patients with a cough from others, and
no dedicated TB ward. Only one medical emergency ward was
equipped with a total of ﬁve extractor fans in isolation rooms.
Large common patient wards without basic measures for
airborne IPC, combined with the high HIV infection prevalence
among inpatients, could provide a prime setting for the rapid
spread of drug-resistant organisms.4 Each PTB patient in our study
was on average transferred twice during their hospitalization, with
eight patients being transferred more than ﬁve times, each ward
transfer posing an increased risk of transmission. This is
particularly relevant, as one ﬁfth of PTB patients (82/394) were
seen in wards or outpatient clinics without routine TB-IPC
precautions. In high incidence countries, these should consistently
and appropriately be applied to risk prone procedures in all areas
of the hospital, not only in areas with TB routine.
It has been shown, that IPC measures can reduce the risk of TB
transmission even in settings with limited resources.32 They
include administrative or work practice, environmental controls,
and respiratory protection. The use of surgical masks and, for high-
risk procedures and contact with MDR-TB patients, N95-respira-
tors, are the mainstay in reducing the chance that inhaled air will
contain infectious tubercle bacilli.33
The ineffective organization of services includes the lack of
reporting and laborious access to crucial clinical information, such
D. Sissolak et al. / International Journal of Infectious Diseases 14 (2010) e423–e428e428as the kind of anti-TB (and HIV) treatment, date of treatment start,
and date of notiﬁcation. These data should be part of each PTB
patient’s hospital-based electronic register.
The attending clinician who diagnoses TB is responsible for the
notiﬁcation of a patient to the South Africa Provincial Department
of Health. Notiﬁcation is the cornerstone of the NTP, and therefore,
the notiﬁcation failure in 85.8% of cases (338/394)was of particular
concern in our study. We suggest an urgent review of the South
Africa notiﬁcation system, considering the involvement of the
laboratory, and an improvement of the reporting system. As the
down-referral from tertiary hospitals to the district clinics was
recently pointed out as one of theweakest links of TB control in the
Western Cape,34 we recommend the inclusion of the district clinics
into the reporting system of the hospitals.
This study has already served as a basis to involve hospital
management and provincial health authorities into addressing
deﬁned barriers to TB control on different levels. First structural
improvements, such as the installation of negative pressure
ventilation in isolation rooms at one of the high-risk wards and
the establishment of cough rooms in the infectious diseases clinics,
have been made.
Improvements in the organization of services, like training of
staff, including doctors and hospital executive managers, and the
restructuring of the reporting system, have urgently to be
addressed.
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